


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.64%
-3.14%
-1.40%
VTYX
Ventyx Biosciences Inc.
$8.19
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
VTYX Price Performance
$9.5 (-13.79%)
$2.3 (+256.09%)
$3.2 (+155.94%)
$2.38 (+244.12%)
VTYX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

VTYX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
VTYX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
VTYX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is VTYX current stock price?
What are VTYX stock strengths?
What is VTYX Risk Level?
What is VTYX market cap and volume?
What is VTYX current Stock IQ?
Should I buy VTYX stock right now?
Is VTYX a Strong Buy right now?
What does a 'Strong Buy' rating mean for VTYX?
What does a 'Strong Sell' rating mean for VTYX?
What factors influence VTYX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.64%
-3.14%
-1.40%
VTYX
Ventyx Biosciences Inc.
Current Price
$8.19
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

VTYX Price Performance
$9.5 (-13.79%)
$2.3 (+256.09%)
$3.2 (+155.94%)
$2.38 (+244.12%)
VTYX Analysts Opinion
VTYX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
VTYX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
VTYX Street Sentiment is extremely bullish and have positive views on the near-term outlook
VTYX has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
VTYX Stock IQ
VTYX Latest Analysis
Ventyx Provides Clinical and Corporate Updates. Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx'.s R&.D Day planned for Q1 2026SAN DIEGO Dec. 02 2025
Tue Dec 2, 2025
Ventyx Provides Clinical and Corporate Updates. SAN DIEGO Dec. 02 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences Inc. (Nasdaq: VTYX) (Ventyx Company) a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases today announced that the Company added two leading experts to their advisory board and provided an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent per
Tue Dec 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
VTYX Stock trends
VTYX Stock performance
VTYX Stock analysis
VTYX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.